Leading the
global fight
against cancer
 
 

Union for International Cancer ControlUICC

"The Union for International Cancer Control (UICC) unites and supports the cancer community to reduce the global cancer burden, to promote greater equity, and to ensure that cancer control continues to be a priority in the world health and development agenda."

 
Our main missions
icon_convening-orange.png
Convening

Convening the global cancer control community through our keystone events

icon_capacity-building-orange_0.png
Capacity Building

Developing capacity building initiatives to strengthen the cancer community

icon_advocacy-orange.png
Advocacy

Promoting cancer in the global health and development agendas

Our key platforms
icon_wcd-blue.png
World Cancer Day 2023 – 4 Feb

179

days

Latest news and updates
Our news and updates
2020 UICC Awards virtual ceremony.png
Updated on 4 August 2022
18 July 2022
News

UICC announces the nominees for Best CEO and Best World Cancer Day Campaign Awards

UICC looks forward to recognising outstanding achievements, creativity and innovation across the UICC membership at a ceremony that will take place during the UICC General Assembly in October.

Patient hand pours white round medical pills out of bottle
14 July 2022
News

UICC and IFPMA editorial in Re:solve Public Health: “A collective approach can improve access to cancer care.”

Closing the widening access gap to cancer care requires willing collaboration and a collective effort by organisations from across sectors pulling together towards a common ambition.

Man and women hugging before a line of Ukrainian refugees
14 July 2022
News

Emergency funding for cancer care in Ukraine and neighbouring countries

UICC has disbursed the first grants from the Solidarity Fund for Ukraine, which was set up in March, and speaks with one of the grantees, Medical Laboratory CSD in Kyiv.

Healthcare worker looking at a sample at the pathology department at the  Aga Khan University Hospital in Kenya
11 July 2022
News

How to address the gaps in cancer care in sub-Saharan Africa

UICC Board Member Dr Miriam Mutebi comments on a recent Lancet Oncology Commission report, to which she contributed, and offers responses to the rising cancer incidence and mortality in sub-Saharan Africa.

Spotlight on
UNICEF staff member assisting a mother and child in a migrant camp for Venezuelans leaving the country. UNICEF launched a regional response in 2018 to support children and families from Venezuela, as well as children in host communities. Photo ©UNICEF/2018/Moreno
20 June 2022
News

Cancer and social unrest: caring for Venezuelan migrants in Colombia

Marking World Refugee Day, UICC starts a series of articles spotlighting members dispensing cancer care to people displaced by conflict or social instability in their region.

Three doctors at the Shaukat Khanum Memorial Cancer Hospital and Research Centre operating on a patient
5 July 2022
News

Cancer care for Afghan refugees in Pakistan

Dr Sultan of SKMCH&RC talks about the situation with respect to Afghans seeking cancer care in Pakistan and the need for more qualified staff and relevant policies.

Our Partners
Amgen logo
Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

AECC logo.png
Asociación Española Contra el Cancer (AECC)

The Asociación Española Contra el Cáncer (AECC) (Spanish Association Against Cancer) is a non-profit, private social entity which has been declared of public utility. It was founded in 1953. The mission of the AECC is the fight against cancer leading the efforts of the Spanish society to decrease the impact of this disease and to improve the people’s quality of life. Four main strategic pillars guide the activities of the association: information & awareness, cancer patients support, research, and advocacy & lobbying. It is a nation wide organisation with 52 provincial delegations and more than 2.000 local delegations. The association counts on more than 109.000 members, 14.000 volunteers and 730 workers to develop its activities. In 1971, the AECC established its Scientific Foundation which main purpose is to improve cancer research in Spain. The Asociacion Española Contra el Cancer became a full UICC member in 1962.

Astellas
Astellas

The Astellas Group aims to become a R&D-driven global pharmaceutical company contributing to people’s health. Astellas’s business philosophy has three elements — raison d'être, mission and beliefs. This business philosophy expresses the company’s aim to contribute to the health of people around the world through the provision of highly effective and trustworthy pharmaceuticals, while continuously increasing the Company's enterprise value.

bd_color_rgb_2_25.jpg
Beckton, Dickinson and Company

Beckton, Dickinson and Company (BD) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.

Bristol-Myers Squibb Logo
Bristol-Myers Squibb (BMS)

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

CRUK
Cancer Research UK

Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.

CACA logo.jpg
China Anti-Cancer Association (CACA)

Established in 1984, the China Anti-Cancer Association (CACA) is a non-government and non-profit organisation with a mission to unite people involved in all branches of oncology with a shared interest in fighting cancer. CACA is dedicated to improving cancer control in China through increasing the survival rates, and decreasing the incidence and mortality rates of cancer. CACA plays an important role in promoting academic exchange, organising public education, establishing collaboration with international cancer societies, and providing data and advice to the Chinese government for making strategies and policies on cancer control. The branches consist of 45 professional societies, 47 full membership organisations, and 30 local anti-cancer associations with a total membership exceeding 47,000.

Fondation Philantropia
Fondation Philantropia

An umbrella foundation associated with the bank Lombard Odier and a registered charity, Fondation Philanthropia has been helping its donors bring their philanthropic initiatives to fruition in all areas of social responsibility since 2008. It provides philanthropic expertise and support to those who wish to develop a philanthropic project in line with their background, desires and ambitions. The Foundation offers its donors a legal, financial and philanthropic framework for made-to-measure projects.

The Foundation now operates more than 20 personal funds and has received over 115 million Swiss francs in donations, of which over a third has already been distributed or committed. Its donors have been highly committed to the fight against cancer, with over 15 million spent on the cause.

hologic logo.png
Hologic

Hologic, Inc. is a global medical technology innovator primarily focused on improving women’s health and well-being through early detection and treatment. Its advancements include leadership in providing diagnostic solutions for cervical cancer screening, sexually transmitted infections, respiratory illnesses, and the virus that causes COVID-19; invention of the world’s first commercial 3D mammography system to fight breast cancer; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding. The company champions women through the Hologic Global Women’s Health Index, which provides a science-backed data roadmap for improving women’s well-being, and Project Health Equality, which elevates awareness, research insights and access to quality care for underserved women.

ICONGROUP__CMYK_Logo.png
ICON Group

Icon Group is a leading provider of cancer care across Australasia. Icon believes in bringing the best cancer treatment possible, to as many people as possible, as close to home as possible. They do this through leveraging the latest technology, collaborating with like-minded partners and investing in outstanding people.

Institut National du Cancer
Institut National du Cancer

The French National Cancer Institute (INCa) was established under the French Public Health Act of August 9, 2004, as the State health and science agency specialised in cancer control. The Institute operates under the supervision of the French Ministry of Health and Solidarities and the French Ministry of Higher Education, Research and Innovation. It provides an integrated approach encompassing all cancer-control aspects (health, scientific, social and economic) and intervention areas (prevention, screening, care, research) to benefit patients and their relatives. The Institute is also a trusted source of evidence-based information, providing reliable advice on cancer control to government and guidance to health professionals and the community. The Institute drives the implementation of the French decennial strategy against cancer (2021-2030): it plays a pivotal role in maximising coordination amongst cancer control stakeholders to enhance impact.

kom-op-tegen-kanker-logo-vector.png
Kom Op Tegen Kanker – Stand Up To Cancer Flanders

‘You have cancer.’ More than 40,000 Flemish people are given this diagnosis every year. 1 in 4 women develop the disease before the age of 75. In men it is even 1 in 3. Fortunately, survival rates are up. This means increasingly more people live with the consequences of cancer. In Flanders more than a quarter of a million already. Kom op tegen Kanker (Stand up to Cancer), an independent ngo and non-profit organisation, plays a leading role in this and is the point of contact in the fight against cancer in Flanders and Brussels. Our dream? A world in which we no longer lose loved ones to cancer. But we're not there yet. We will fight until this dream becomes reality. How? By preventing and fighting cancer. But also by alleviating the effects of cancer and advocating a better cancer policy. To be able to do this, we mobilise as many people as possible to fight against cancer: as care volunteer, campaigner or donor.  Find out more about our organisation and how you can help on komoptegenkanker.be.  

LP56860-lrp-retail-brand-white-logo (002).png
La Roche-Posay

N°1 dermatologist recommended skincare brand worldwide, La Roche-Posay’s mission is to offer life-changing dermatological skincare solutions. Recommended by 90,000 dermatologists worldwide*, La Roche-Posay was created by a pharmacist in 1975. The brand is today present in over 60 countries. It offers a unique range of daily skincare developed for every skin type to complement their dermatological treatments and promote good skincare practices adapted to each skin concern. The brand develops formulas with its exclusive Selenium-rich water, also used at its Thermal Center, the first Dermatology Center in Europe, due to its antioxidant and soothing properties. The products are developed using a strict formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety, even on sensitive skin.  The La Roche-Posay Cancer Support program includes two pillars related to the fight against cancer: Fight With Care to improve patients’ quality of life during all cancer treatment for better adherence and higher chances of healing, and Save Your Skin to prevent skin cancer specifically. On both topics, the brand is committed to raising awareness, training health care professional and the general public, and helping patients by supporting NGOs’ projects beyond skincare. Since 2019, the Fondation La Roche-Posay is also committed to improving the life of children with cancer and their families. In 2020, the brand went a step further in its commitment to protect the planet. Besides launching the first eco-designed tubes integrating cardboard, the brand announced a long-term plan to reduce its use of virgin plastic by 70% in 2025.

For additional information about La Roche-Posay, visit www.laroche-posay.com.

*source: survey on the dermocosmetic market carried out by iqvia and other partners (ipsos, tns) between september 2017 and august 2018 among dermatologists in 62 countries.

 

MSD be well
MSD (Merck & Co)

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

National Cancer Institute (NCI)
National Cancer Institute (NCI)

The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Novartis logo
Novartis Oncology

Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.

Pfizer logo
Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

Roche logo
Roche

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide.

Sanofi
Sanofi

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.

Swiss Cancer League
Swiss Cancer League

The Swiss Cancer League is a national, charitable, private organisation, founded in 1910. It is the Berne-based headquarter of an association of 19 regional cancer leagues. The Swiss Cancer League covers all aspects of cancer, with the aim of ensuring that fewer people develop cancer, fewer people suffer and die from the consequences of cancer and more people can be treated successfully. The organisation supports innovative cancer research projects, increases public awareness of prevention measures and is committed to early diagnosis and treatment. One of its first concerns is to ensure high-quality advice and psychological support for all cancer patients and survivors and their caretakers. The Swiss Cancer League also supports other cancer control organisations in low income countries.

UICC Japan
UICC Japan

The Japan National Committee for UICC is a group of Japanese organisations that are members of the Union for International Cancer Control (UICC), gathered to support the UICC to strive to realise the World Cancer Declaration. Currently UICC-Japan is composed of 29 full Japanese UICC members, including major cancer specialists in Japan, cancer centres, research institutes, research funds, hospitals and cancer associations.

Give us
your support
 

Are you organising a cancer-related event and would like to feature it in our events section?

 

Are you interested in joining a dynamic network of over 1,000 members?

 

Would you like to support the work of UICC and its member organisations?